Overview

  • Product name

    Anti-KRIT1 antibody [EPR16560]
    See all KRIT1 primary antibodies
  • Description

    Rabbit monoclonal [EPR16560] to KRIT1
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Human
  • Immunogen

    Recombinant fragment within Human KRIT1 aa 1-150. The exact sequence is proprietary.
    Database link: O00522

  • Positive control

    • Human fetal brain and Mouse brain lysates; SH-SY5Y, Raji, NIH/3T3 and HUVEC cell lysates; HUVEC cells.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab196025 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 84 kDa (predicted molecular weight: 84 kDa).
ICC/IF 1/100.

Target

  • Function

    Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits EKR1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin D1 levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels.
  • Tissue specificity

    Low levels in brain. Very weak expression found in heart and muscle.
  • Involvement in disease

    Defects in KRIT1 are the cause of cerebral cavernous malformations type 1 (CCM1) [MIM:116860]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.
  • Sequence similarities

    Contains 4 ANK repeats.
    Contains 1 FERM domain.
  • Cellular localization

    Membrane. Cell junction. KRIT1 and CDH5 reciprocally regulate their localization to endothelial cell-cell junctions.
  • Information by UniProt
  • Database links

  • Alternative names

    • Ankyrin repeat containing protein Krit1 antibody
    • CAM antibody
    • CCM 1 antibody
    • CCM1 antibody
    • Cerebral cavernous malformations 1 antibody
    • Cerebral cavernous malformations 1 protein antibody
    • Krev interaction trapped 1 antibody
    • Krev interaction trapped protein 1 antibody
    • KRIT 1 antibody
    • KRIT1 ankyrin repeat containing antibody
    • KRIT1 antibody
    • KRIT1_HUMAN antibody
    see all

Images

  • All lanes : Anti-KRIT1 antibody [EPR16560] (ab196025) at 1/5000 dilution

    Lane 1 : Human fetal brain lysate
    Lane 2 : SH-SY5Y (Human neuroblastoma from bone marrow cells) cell lysate
    Lane 3 : Raji (Human Burkitt's lymphoma cell line) cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 84 kDa
    Observed band size: 84 kDa



    Blocking/Dilution buffer: 5% NFDM/TBST.

  • All lanes : Anti-KRIT1 antibody [EPR16560] (ab196025) at 1/1000 dilution

    Lane 1 : Mouse brain lysate
    Lane 2 : NIH/3T3 (Mouse embyro fibroblast cells) cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 84 kDa
    Observed band size: 84 kDa



    Blocking/Dilution buffer: 5% NFDM/TBST.

  • Anti-KRIT1 antibody [EPR16560] (ab196025) at 1/5000 dilution + HUVEC (Human umbilical vein endothelial cell line) whole cell lysate at 10 µg

    Secondary
    Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 84 kDa
    Observed band size: 84 kDa



    Blocking/Dilution buffer: 5% NFDM/TBST.

  • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (Human umbilical vein endothelial cell line) cells labeling KRIT1 with ab196025 at 1/100 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/500 dilution (green). Cytoplasm staining on HUVEC cell line is observed. The nuclear counter stain is DAPI (blue). Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution (red).
    The negative controls are as follows:
    -ve control 1: ab196025 at 1/100 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution.
    -ve control 2: ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/500 dilution.

References

This product has been referenced in:

  • Cianfruglia L  et al. KRIT1 Loss-Of-Function Associated with Cerebral Cavernous Malformation Disease Leads to Enhanced S-Glutathionylation of Distinct Structural and Regulatory Proteins. Antioxidants (Basel) 8:N/A (2019). Read more (PubMed: 30658464) »
  • La Sala L  et al. Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. Cardiovasc Diabetol 17:105 (2018). Read more (PubMed: 30037352) »
See all 3 Publications for this product

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A

Application
Western blot
Sample
Mouse Cell lysate - whole cell (mouse embryonic stem cells (mESCs))
Gel Running Conditions
Reduced Denaturing (10%)
Loading amount
50 µg
Specification
mouse embryonic stem cells (mESCs)
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C

Abcam user community

Verified customer

Submitted Dec 14 2017

Application
Western blot
Sample
Human Cell lysate - whole cell (HeLa, Mel202, A431, HCT116, JURKAT, RAJI)
Gel Running Conditions
Reduced Denaturing
Loading amount
30 µg
Specification
HeLa, Mel202, A431, HCT116, JURKAT, RAJI
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

Abcam user community

Verified customer

Submitted Jul 22 2016

Application
Immunoprecipitation
Sample
Mouse Cell lysate - whole cell (Mouse Embrionic Fibroblasts non expressing (K -/-))
Total protein in input
500 µg
Immuno-precipitation step
Protein A
Specification
Mouse Embrionic Fibroblasts non expressing (K -/-)

Lorenza Trabalzini

Verified customer

Submitted Nov 26 2015

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up